Dupilumab Provides Favorable Safety and Sustained Efficacy for Up To 3 Years in an Open-Label Study of Adults With Moderate-to-Severe Atopic Dermatitis
mediaposted on 2020-06-18, 07:57 authored by Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Andrew Blauvelt, Robert Bissonnette, Marjolein de Bruin-Weller, Michihiro Hide, Lawrence Sher, Iftikhar Hussain, Zhen Chen, Faisal A. Khokhar, Bethany Beazley, Marcella Ruddy, Naimish Patel, Neil M.H. Graham, Marius Ardeleanu, Brad Shumel
Article full text
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above video and key summary points represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.